TrialThe New England journal of medicine2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Sean Wharton et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
215 papers cite itlatest 60 shown
this paperpooled ittrialcites it